Stealth tanshinone IIA-loaded solid lipid nanoparticles: Effects of poloxamer 188 coating on in vitro phagocytosis and in vivo pharmacokinetics in rats

Yaoxue Xuebao

Volumn 44, Issue 12, 2009, Pages 1421-1428

  Zhang, Wen Li ^a   Liu, Jian Ping ^a   Liu, Xiao Xu ^a   Chen, Zhi Qiang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Nanoparticle; Phagocytosis; Pharmacokinetics; Tanshinone IIA

Indexed keywords

POLOXAMER; SOLID LIPID NANOPARTICLE; TANSHINONE IIA;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; MACROPHAGE; MALE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; RAT; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; DITERPENES, ABIETANE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUGS, CHINESE HERBAL; LIPIDS; MACROPHAGES; MALE; MICE; NANOPARTICLES; PARTICLE SIZE; PHAGOCYTOSIS; PLANTS, MEDICINAL; POLOXAMER; RATS; RATS, SPRAGUE-DAWLEY; SALVIA MILTIORRHIZA;

EID: 76249133107     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Grislain L, Couvreur P, Lenaerts V, et al. Pharmacokinetics and distribution of a biodegradable drug-carrier [J]. Int J Pharm, 1983, 15: 335-345.
2. Illium L, Davis SS, Wilson CG, et al. Blood clearance and organ deposition of intravenously administered colloidal particles: the effect of particle size, nature and shape [J]. Int J Pharm, 1982, 12: 135-146.
3. Fundaro A, Cavalli R, Bargoni A, et al. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after iv administration to rats [J]. Pharmacol Res, 2000, 42: 337-343.
4. Lu W, He LC, Wang CH, et al. The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice [J]. Int J Biol Macromol, 2008, 43: 320-324.
5. Fang C, Shi B, Hong MH, et al. Influence of particle size and MePEG molecular weight on in vitro macrophage uptake and in vivo long circulating of stealth nanoparticles in rats [J]. Acta Pharma Sin, 2006, 41: 305-312.
6. Litzinger DC, Buiting AM, Rooijen N, et al. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic PEG polyethylene glycol)-containing liposomes [J]. Biochim Biophys Acta, 1994, 1190: 99-107.
7. Zhao BL, Jiang W, Zhao Y, et al. Scavenging effects of Savia miltiorrhiza on free radical and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury [J]. Biochem Mol Biol Int, 1996, 38: 1171-1182.
8. Li QF, Shi SL, Liu QR, et al. Anticancer effects of ginsenoside Rg1, cinnamic acid, and tanshinone IIA in osteosarcoma MG-63 cells: nuclear matrix downregulation and cytoplasmic trafficking of nucleophosmin [J]. Int J Biochem Cell Biol, 2008, 40: 1918-1929.
9. Yuan SL, Wang XJ, Wei YQ. Anticancer effect of tanshinone and its mechanisms [J]. Cancer, 2003, 22: 1363-1366.
10. Wang X, Wei Y, Yuan S, et al. Potential anticancer activity of tanshinone IIA against human breast cancer [J]. Int J Cancer, 2005, 116: 799-807.
11. Su CC, Lin YH. Tanshinone IIA down-regulates the protein expression of ErbB-2 and up-regulates TNF-alpha in colon cancer cells in vitro and in vivo [J]. Int J Mol Med, 2008, 22: 847-851.
12. Fu J, Huang H, Liu J, et al. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis [J]. Eur J Pharmacol, 2007, 568: 213-221.
13. Li XL, Li XR, Wang LJ, et al. Simultaneous determination of danshensu, ferulic acid, cryptotanshinone and tanshinone IIA in rabbit plasma by HPLC and their pharmacokinetic application in danxiongfang [J]. J Pharm Biomed Anal, 2007, 44: 1106-1112.
14. Hao HP, Wang GJ, Cui N, et al. Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation [J]. Curr Drug Metab, 2007, 8: 137-149.
15. Li Q, Wang Y, Feng N, et al. Novel polymeric nanoparticles containing tanshinone IIA for the treatment of hepatoma [J]. J Drug Target, 2008, 16: 725-732.
16. Liang Z, Mao SJ, Yin ZN, et al. Preparation and quality evaluation of intravenous tanshinone II (A) emulsion [J]. China J Chin Mater Med, 2008, 33: 1249-1252.
17. Li HL, Zhang ZY, Ma LL, et al. Preparation of tanshinone microemulsion and its absorption in rat intestine in situ [J]. China J Chin Mater Med, 2007, 32: 1024-1027.
18. Chu MQ, Gu HC, Liu GJ. Study on the preparation of tanshinone proliposomes by spray drying method [J]. Chin Pharm J, 2002, 37: 32-35.
19. Liang L, Chen Y, Xiong S, et al. The inhibitive effect produced by local perfusion of tanshinone IIA nanoparticle on neointimal hyperplasia of rabbit carotid artery following intimal denudation [J]. J Biomed Eng, 2007, 24: 812-816.
20. Zhang WL, Liu JP, Li SC, et al. Preparation and evaluation of stealth tashinone IIA-loaded solid lipid nanoparticles: Influence of Poloxamer 188 coating on phagocytic uptake [J]. J Microencapsul, 2008, 25: 203-209.
21. Li JC, Sha XY, Zhang LJ, et al. 9-nitrocamptothecin nanostructure lipid carrier system: in vitro releasing characteristics, uptake by cells, and tissue distribution in vivo [J]. Acta Pharm Sin, 2005, 40: 970-975.
22. Song M, Hang TJ, Zhang ZX. Pharmacokinetic interactions between the main components in the extracts of Salvia miltiorrhiza Bge in rat [J]. Acta Pharma Sin, 2007, 42: 301-307.
23. Giacomo F, Mariano L, Silvana M, et al. Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake [J]. Biomaterials, 2001, 22: 2857-2865.
24. Bunjes H, Westesen K. Do nanoparticles prepared from lipids solids at room temperature always possess a solid lipid matrix ? [J]. Int J Pharm, 1995, 115: 129-131.
25. Mehnert W, Mader K. Solid lipid nanoparticles: production characterization and applications [J]. Adv Drug Deliv Rev, 2001, 47: 165-196.
26. Westesen K, Siekmann B, Koch MHJ. Investigations on the physical state of the lipid nanoparticles by synchrotron radiation X-ray diffraction [J]. Int J Pharm, 1993, 93: 189-199.
27. Frank M, Fries L. The role of complement in inflammation and phagocytosis [J]. Immunol Today , 1991, 12: 322-326.
28. Antonsen KP, Hoffman AS. Water structure of PEG solutions by differential calorimetry measurements [M]//Harris JM, editor. Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications. New York: Plenum Press, 1992: 15-27.
29. Nagaoka S, Mori Y, Tanzawa H, et al. Interaction between blood components and hydrogels with poly(oxyethylene) chains [M]//Shalaby SW, Hofman AS, Ratner DB, et al, editor. Polymers as Biomaterials. New York: Plenum Press, 1984: 361-374.
30. Coleman DL, Gregonis DE, Andrade JD. The minimum interfacial free energy and optimum polar/apolar ratio hypothesis [J]. J Biomed Mater Res, 1982, 16: 381-398.
31. Li XL, Li XR, Wang LJ, et al. Simultaneous determination of danshensu, ferulic acid, cryptotanshinone and tanshinone IIA in rabbit plasma by HPLC and their pharmacokinetic application in danxiongfang [J]. J Pharm Biomed Anal, 2007, 44: 1106-1112.
32. Qiao JP, Hou PL, Li YW, et al. Determination of tanshinone IIA in rat plasma and the pharmacokinetics by RP-HPLC method [J]. Acta Pharma Sin, 2003, 38: 368-370.
33. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration [J]. J Control Release, 2005, 107: 215-228.
34. Chen DB, Yang TZ, Lu WL, et al. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel [J]. Chem Pharm Bull, 2001, 49: 1444-1447.
35. Jeon SI, Lee JH, Andrade JD, et al. Protein-surface interactions in the presence of polyethylene oxide I [J]. J Colloid Interface Sci, 1991, 142: 149-158.